Trusted Resources: News & Meetings
Latest announcements and gatherings
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market Research Report – Global Clinical Trials Review, H2, 2021 – ResearchAndMarkets.com
The “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. The clinical trial report provides an overview of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome).
Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
BookmarkRelated Content
-
University of Minnesota – Mucopolysaccharidosis (MPS) CenterOur MPS Center is internationally recogn...
-
The MPS I-H Diagnostic Journeyhttps://www.youtube.com/watch?v=jSq5tQD4...
-
Stewart RustDr Rust completed his first degree at Le...
-
The Ryan FoundationChildren with rare diseases are racing t...
-
Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzy...Cardiovascular involvement is among the ...
-
Open-Label Phase 1/2 Study of Vestronidase Alfa for Mucopolysaccharidosis VIIVestronidase alfa is an enzyme replaceme...
-
Advances in Approaches to Care and Monitoring of MPS Diseasehttps://www.youtube.com/watch?v=JZSVzeiX...
Powered by
